Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms Deuterated [18F]hexadeuterofluoropropyl-(+)-dihydrotetrabenazine, FLUORINE-18 P17 059, [18F]D6-FP-DTBZ + [1] |
Target |
Action inhibitors |
Mechanism VMAT2 inhibitors(Synaptic vesicular amine transporter inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Parkinson Disease | Phase 1 | United States | 15 Jul 2022 |
Not Applicable | - | - | D6-[18F]FP-(+)-DTBZ | hmgbtorvhy(pqjpebqlua) = a substantial reduction in VMAT2 uptake in the putamen cpfiotwumk (rhpuaznjxk ) View more | - | 09 Jun 2024 |